DC Universe Reborn
Superman's $122 million opening weekend has launched James Gunn's DC Universe to a powerful start. This carefully selected group of stocks includes companies positioned to benefit across the entertainment ecosystem, from the studio to theaters and merchandise partners.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
WARNER BROS DISCOVERY INC
WBD
Current price
$11.56
As the parent company of DC Studios and Warner Bros. Pictures, its financial success is directly tied to the box office performance of the 'Superman' ...
As the parent company of DC Studios and Warner Bros. Pictures, its financial success is directly tied to the box office performance of the 'Superman' franchise.
About This Group of Stocks
Our Expert Thinking
Superman's successful debut signals a revitalized DC franchise with multi-year potential. This creates a ripple effect across entertainment, benefiting not just the studio but also theaters, toy manufacturers, and merchandise partners. The renewed franchise promises recurring, diversified revenue streams.
What You Need to Know
This collection offers exposure to entertainment and consumer discretionary sectors with cyclical, high-growth potential. The stocks represent key points in the superhero ecosystem, from production and distribution to licensed consumer products, creating a diversified approach to this entertainment theme.
Why These Stocks
These companies were selected because they directly benefit from a successful superhero franchise. The portfolio includes the parent studio that profits from box office returns, theater chains that see increased attendance, and merchandise partners that capitalize on fan enthusiasm through toys and collectibles.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+31.54%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 31.54% over the next year.
Stocks Rated Buy by Analysts
13 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Superhero-Sized Potential
Superman's $122 million opening isn't just a one-weekend win. It signals the start of an entire universe of films that could create years of revenue for these companies.
The Entertainment Web
One blockbuster success creates ripples across multiple industries. From theater attendance to toy sales to theme park visits, these stocks capture different ways to profit from superhero mania.
Just Getting Started
This is just the first film in James Gunn's ambitious DC Universe plan. Each successful release could further boost these companies as the franchise builds momentum and fan loyalty.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.